Across TCGA pan-cancer cohorts, MAP7D2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP7D2 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MAP7D2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP7D2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and THCA are the cancer types where MAP7D2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.083	0.553	.009	12	view →
UCEC	OS	Median	II,III,IV	0.890	0.454	.030	10	view →
THCA	DFS	Median	All	0.081	0.841	<.001	6	view →
COAD	OS	Median	III,IV	0.054	0.793	<.001	6	view →
SKCM	OS	Median	All	0.086	0.399	.006	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MAP7D2 tumor-vs-normal RNA expression · all MAP7D2 data types